SPECT/CT Device for Theranostic Imaging Debuts at EANM Meeting

News
Article

Designed for theranostic imaging applications, the AnyScan Trio SPECT/CT TheraMax scanner was recently unveiled at the annual meeting of the European Association of Nuclear Medicine (EANM).

Offering enhanced sensitivity and spatial resolution capability approaching that of positron emission tomography (PET), the AnyScan Trio SPECT/CT TheraMax system was introduced at the European Association of Nuclear Medicine (EANM) annual conference in Hamburg, Germany.

Designed with an emphasis on targeted radionuclide therapy applications, the AnyScan Trio SPECT/CT TheraMax platform includes detectors and collimators that enable the use of alpha- and beta-emitting radiopharmaceuticals as well as high-energy gamma photons such as lutetium-177 (177Lu) and actinium-225 (225Ac), according to Mediso, the manufacturer of the AnyScan Trio SPECT/CT TheraMax device.

SPECT/CT Device for Theranostic Imaging Debuts at EANM Meeting

Recently installed at the University Hospital Regensburg in Regensburg, Germany, the AnyScan Trio SPECT/CT TheraMax system was designed with an emphasis on targeted radionuclide therapy applications, according to Mediso, the manufacturer of the system. (Photo courtesy of Mediso.)

The company noted that other features and capabilities of the system include:

• surface detectors up to five times larger than those utilized in 12-detector cadmium zinc telluride (CZT) platforms;

• PET-like image quality with bolstered spatial resolution facilitated by the platform’s high-density sensor arrangement;

• whole-body SPECT/CT scans with up to 300 percent higher sensitivity in comparison to conventional dual-detector devices; and

• integrated computed tomography (CT) options for low-dose, ultra-low dose and “zero-dose” protocols with artificial intelligence (AI)-enabled SyCT (Synthetic CT).

"With the development of the new TheraMAX, we extended the imaging capabilities of nuclear medicine departments by improving the diagnostic confidence of SPECT/CT examinations close to PET/CT," said Istvan Bagaméry, the managing director of Mediso. "The TheraMAX transforms the clinical routine also with ultra-fast quantitative total-body scans."

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Related Content
© 2025 MJH Life Sciences

All rights reserved.